Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 5361-5370 Newer>

The Motley Fool January 15, 2009 Robert Steyer	For Pfizer, a Big Buy Could Be a Big Mistake Pfizer's CEO says the company must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Is it the right move?
The Motley Fool January 14, 2009 Brian Orelli	FDA's Bipolar Decision on Schering's Drug Signs point to an approval for Schering-Plough's schizophrenia and bipolar drug Saphris, but there isn't one yet.
The Motley Fool January 14, 2009 Brian Orelli	ZymoGenetics, the Pharmaceutical Zombie ZymoGenetics deal with Bristol-Myers may bring the drug developer stumbling back from the dead.
The Motley Fool January 13, 2009 Brian Orelli	Celgene's Still Surging With returns over the last five years that just about any investor would love to have, it might be fair to wonder whether Celgene can keep it up. It seems it can.
The Motley Fool January 12, 2009 Brian Orelli	Abbott Eyes New Growth Abbott announces it's buying eye-care specialist Advanced Medical Optics for $22 per share -- nearly 150% higher than Friday's close on the stock.
The Motley Fool January 12, 2009 Brian Orelli	Trust Management or Don't Buy American Oriental Bioengineering, purveyor of traditional Chinese medical products, bought a $70 million building to use as a "Convention and Training Center," and investors aren't happy about it.
Pharmaceutical Executive January 1, 2009 Amit Agarwal	Overlooked Opportunities For pharma companies facing a difficult economic climate, pairing diagnostics with therapies offers a powerful incentive: Manufacturers can improve sales by helping physicians find the most appropriate therapeutic option.
Pharmaceutical Executive January 1, 2009 Walter Armstrong	Up in the Air If pharma execs start upping their consumption of antihypertensives and anxiolytics (all branded, of course) in the months to come, it won't be a huge surprise. The industry faces a truly unprecedented number of political and policy challenges.
Pharmaceutical Executive January 1, 2009 Stan Bernard	Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms.
Pharmaceutical Executive January 1, 2009 Carrie Fisher	Uneven Landscape The headlines are about layoffs, but some segments of pharma are still hiring. Pay, meanwhile, tightens.
<Older 5361-5370 Newer> Return to current articles.